402 related articles for article (PubMed ID: 16639410)
1. Germline fumarate hydratase mutations in patients with ovarian mucinous cystadenoma.
Ylisaukko-oja SK; Cybulski C; Lehtonen R; Kiuru M; Matyjasik J; Szymañska A; Szymañska-Pasternak J; Dyrskjot L; Butzow R; Orntoft TF; Launonen V; Lubiñski J; Aaltonen LA
Eur J Hum Genet; 2006 Jul; 14(7):880-3. PubMed ID: 16639410
[TBL] [Abstract][Full Text] [Related]
2. Fumarate hydratase mutations and predisposition to cutaneous leiomyomas, uterine leiomyomas and renal cancer.
Alam NA; Olpin S; Leigh IM
Br J Dermatol; 2005 Jul; 153(1):11-7. PubMed ID: 16029320
[TBL] [Abstract][Full Text] [Related]
3. Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families.
Kiuru M; Lehtonen R; Arola J; Salovaara R; Järvinen H; Aittomäki K; Sjöberg J; Visakorpi T; Knuutila S; Isola J; Delahunt B; Herva R; Launonen V; Karhu A; Aaltonen LA
Cancer Res; 2002 Aug; 62(16):4554-7. PubMed ID: 12183404
[TBL] [Abstract][Full Text] [Related]
4. Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis.
Smit DL; Mensenkamp AR; Badeloe S; Breuning MH; Simon ME; van Spaendonck KY; Aalfs CM; Post JG; Shanley S; Krapels IP; Hoefsloot LH; van Moorselaar RJ; Starink TM; Bayley JP; Frank J; van Steensel MA; Menko FH
Clin Genet; 2011 Jan; 79(1):49-59. PubMed ID: 20618355
[TBL] [Abstract][Full Text] [Related]
5. No germline FH mutations in familial breast cancer patients.
Kiuru M; Lehtonen R; Eerola H; Aittomäki K; Blomqvist C; Nevanlinna H; Aaltonen LA; Launonen V
Eur J Hum Genet; 2005 Apr; 13(4):506-9. PubMed ID: 15523491
[TBL] [Abstract][Full Text] [Related]
6. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer.
Tomlinson IP; Alam NA; Rowan AJ; Barclay E; Jaeger EE; Kelsell D; Leigh I; Gorman P; Lamlum H; Rahman S; Roylance RR; Olpin S; Bevan S; Barker K; Hearle N; Houlston RS; Kiuru M; Lehtonen R; Karhu A; Vilkki S; Laiho P; Eklund C; Vierimaa O; Aittomäki K; Hietala M; Sistonen P; Paetau A; Salovaara R; Herva R; Launonen V; Aaltonen LA;
Nat Genet; 2002 Apr; 30(4):406-10. PubMed ID: 11865300
[TBL] [Abstract][Full Text] [Related]
7. [From gene to disease; cutaneous leiomyomatosis].
Badeloe S; van Geel M; van Steensel MA; Steijlen PM; Poblete-Gutiérrez P; Frank JA
Ned Tijdschr Geneeskd; 2007 Feb; 151(5):300-4. PubMed ID: 17326474
[TBL] [Abstract][Full Text] [Related]
8. Germline fumarate hydratase mutations and evidence for a founder mutation underlying multiple cutaneous and uterine leiomyomata.
Chuang GS; Martinez-Mir A; Geyer A; Engler DE; Glaser B; Cserhalmi-Friedman PB; Gordon D; Horev L; Lukash B; Herman E; Cid MP; Brenner S; Landau M; Sprecher E; Garcia Muret MP; Christiano AM; Zlotogorski A
J Am Acad Dermatol; 2005 Mar; 52(3 Pt 1):410-6. PubMed ID: 15761418
[TBL] [Abstract][Full Text] [Related]
9. Conventional renal cancer in a patient with fumarate hydratase mutation.
Lehtonen HJ; Blanco I; Piulats JM; Herva R; Launonen V; Aaltonen LA
Hum Pathol; 2007 May; 38(5):793-6. PubMed ID: 17270241
[TBL] [Abstract][Full Text] [Related]
10. Mutation screening of fumarate hydratase by multiplex ligation-dependent probe amplification: detection of exonic deletion in a patient with leiomyomatosis and renal cell cancer.
Ahvenainen T; Lehtonen HJ; Lehtonen R; Vahteristo P; Aittomäki K; Baynam G; Dommering C; Eng C; Gruber SB; Grönberg H; Harvima R; Herva R; Hietala M; Kujala M; Kääriäinen H; Sunde L; Vierimaa O; Pollard PJ; Tomlinson IP; Björck E; Aaltonen LA; Launonen V
Cancer Genet Cytogenet; 2008 Jun; 183(2):83-8. PubMed ID: 18503824
[TBL] [Abstract][Full Text] [Related]
11. Increased risk of cancer in patients with fumarate hydratase germline mutation.
Lehtonen HJ; Kiuru M; Ylisaukko-Oja SK; Salovaara R; Herva R; Koivisto PA; Vierimaa O; Aittomäki K; Pukkala E; Launonen V; Aaltonen LA
J Med Genet; 2006 Jun; 43(6):523-6. PubMed ID: 16155190
[TBL] [Abstract][Full Text] [Related]
12. Evidence for a founder effect of the germline fumarate hydratase gene mutation R58P causing hereditary leiomyomatosis and renal cell cancer (HLRCC).
Heinritz W; Paasch U; Sticherling M; Wittekind C; Simon JC; Froster UG; Renner R
Ann Hum Genet; 2008 Jan; 72(Pt 1):35-40. PubMed ID: 17908262
[TBL] [Abstract][Full Text] [Related]
13. Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma.
Gardie B; Remenieras A; Kattygnarath D; Bombled J; Lefèvre S; Perrier-Trudova V; Rustin P; Barrois M; Slama A; Avril MF; Bessis D; Caron O; Caux F; Collignon P; Coupier I; Cremin C; Dollfus H; Dugast C; Escudier B; Faivre L; Field M; Gilbert-Dussardier B; Janin N; Leport Y; Leroux D; Lipsker D; Malthieu F; McGilliwray B; Maugard C; Méjean A; Mortemousque I; Plessis G; Poppe B; Pruvost-Balland C; Rooker S; Roume J; Soufir N; Steinraths M; Tan MH; Théodore C; Thomas L; Vabres P; Van Glabeke E; Meric JB; Verkarre V; Lenoir G; Joulin V; Deveaux S; Cusin V; Feunteun J; Teh BT; Bressac-de Paillerets B; Richard S;
J Med Genet; 2011 Apr; 48(4):226-34. PubMed ID: 21398687
[TBL] [Abstract][Full Text] [Related]
14. Strong family history of uterine leiomyomatosis warrants fumarate hydratase mutation screening.
Tolvanen J; Uimari O; Ryynänen M; Aaltonen LA; Vahteristo P
Hum Reprod; 2012 Jun; 27(6):1865-9. PubMed ID: 22473397
[TBL] [Abstract][Full Text] [Related]
15. [Hereditary leiomyomatosis and renal cell cancer - HLRCC/multiple cutaneous and uterine leimomyomatosis - MCUL].
Plevová P; Hladíková A; Tesařová M
Klin Onkol; 2012; 25 Suppl():S55-8. PubMed ID: 22920208
[TBL] [Abstract][Full Text] [Related]
16. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.
Sanz-Ortega J; Vocke C; Stratton P; Linehan WM; Merino MJ
Am J Surg Pathol; 2013 Jan; 37(1):74-80. PubMed ID: 23211287
[TBL] [Abstract][Full Text] [Related]
17. Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors.
Lehtonen R; Kiuru M; Vanharanta S; Sjöberg J; Aaltonen LM; Aittomäki K; Arola J; Butzow R; Eng C; Husgafvel-Pursiainen K; Isola J; Järvinen H; Koivisto P; Mecklin JP; Peltomäki P; Salovaara R; Wasenius VM; Karhu A; Launonen V; Nupponen NN; Aaltonen LA
Am J Pathol; 2004 Jan; 164(1):17-22. PubMed ID: 14695314
[TBL] [Abstract][Full Text] [Related]
18. Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.
Kopp RP; Stratton KL; Glogowski E; Schrader KA; Rau-Murthy R; Russo P; Coleman JA; Offit K
Cancer; 2017 Jul; 123(13):2452-2458. PubMed ID: 28171700
[TBL] [Abstract][Full Text] [Related]
19. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome.
Merino MJ; Torres-Cabala C; Pinto P; Linehan WM
Am J Surg Pathol; 2007 Oct; 31(10):1578-85. PubMed ID: 17895761
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of somatic and germline mutations of Fumarate hydratase in uterine leiomyomas from young patients.
Liu C; Dillon J; Beavis AL; Liu Y; Lombardo K; Fader AN; Hung CF; Wu TC; Vang R; Garcia JE; Xing D
Histopathology; 2020 Feb; 76(3):354-365. PubMed ID: 31564060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
